Loading…
Clemex Technologies entered into a merger agreement with a purchaser owned by principal shareholders (including RAL Diagnostics, Zwick Roell AG, and CEO Yves Bassat) to acquire all outstanding shares for $0.20 per share, totaling about $3.8 million.
“The Purchaser will purchase, in effect, all of the issued and outstanding Class A common shares of Clemex, other than shares held directly or indirectly by the Principal Shareholders, at a price of $0.20 in cash per share.”newswire.ca
Summarized from public sources; check the original articles before acting on it.